Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
47.58 (1y: +21%)
Market Cap 144.19 B P/E(ttm) 24.10
Enterprise Value 148.99 B P/B 2.70
MRK- NYSE (USA)
Merck & Co Inc
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$47.58
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.785
MRK's Cash to Debt is ranked higher than
56% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. MRK: 0.785 )
MRK' s 10-Year Cash to Debt Range
Min: 0.37   Max: 1.93
Current: 0.79
0.37
1.93
Equity to Asset 0.5
MRK's Equity to Asset is ranked higher than
55% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. MRK: 0.5 )
MRK' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.53
Current: 0.5
0.37
0.53
Interest Coverage 19.1
MRK's Interest Coverage is ranked higher than
70% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.70 vs. MRK: 19.1 )
MRK' s 10-Year Interest Coverage Range
Min: 4   Max: No Debt
Current: 19.1
F-Score: 4
Z-Score: 3.02
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 19.50
MRK's Operating margin (%) is ranked higher than
87% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.80 vs. MRK: 19.50 )
MRK' s 10-Year Operating margin (%) Range
Min: 5.2   Max: 37.2
Current: 19.5
5.2
37.2
Net-margin (%) 13
MRK's Net-margin (%) is ranked higher than
83% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. MRK: 13 )
MRK' s 10-Year Net-margin (%) Range
Min: 1.9   Max: 47
Current: 13
1.9
47
ROE (%) 11.6
MRK's ROE (%) is ranked higher than
84% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. MRK: 11.6 )
MRK' s 10-Year ROE (%) Range
Min: 1.6   Max: 46
Current: 11.6
1.6
46
ROA (%) 5.8
MRK's ROA (%) is ranked higher than
77% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. MRK: 5.8 )
MRK' s 10-Year ROA (%) Range
Min: 0.8   Max: 17.1
Current: 5.8
0.8
17.1
ROC (Joel Greenblatt) (%) 44.50
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.40 vs. MRK: 44.50 )
MRK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.5   Max: 64.2
Current: 44.5
10.5
64.2
Revenue Growth (%) 6.2
MRK's Revenue Growth (%) is ranked higher than
79% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 6.2 )
MRK' s 10-Year Revenue Growth (%) Range
Min: -18.6   Max: 13.7
Current: 6.2
-18.6
13.7
EBITDA Growth (%) 24.6
MRK's EBITDA Growth (%) is ranked higher than
96% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 24.6 )
MRK' s 10-Year EBITDA Growth (%) Range
Min: -11.3   Max: 24.6
Current: 24.6
-11.3
24.6
EPS Growth (%) -22.9
MRK's EPS Growth (%) is ranked lower than
64% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: -22.9 )
MRK' s 10-Year EPS Growth (%) Range
Min: -34.2   Max: 29.2
Current: -22.9
-34.2
29.2
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

MRK Guru Trades in Q2 2012

Louis Moore Bacon 4,903 sh (New)
Paul Tudor Jones 428,300 sh (+2347.43%)
Manning & Napier Advisors, Inc 361,015 sh (+95.3%)
John Buckingham 28,444 sh (+6.23%)
Ken Fisher 20,975 sh (+0.88%)
Mario Gabelli 328,621 sh (+0.74%)
Vanguard Health Care Fund 35,590,648 sh (+0.57%)
Bill Frels 136,107 sh (+0.39%)
John Hussman 1,500 sh (unchged)
Tom Russo 7,586 sh (unchged)
Murray Stahl 43,771 sh (unchged)
Paul Tudor Jones 300,000 sh (unchged)
James Barrow 21,595 sh (unchged)
Bill Nygren 2,886,535 sh (unchged)
Prem Watsa 8,000 sh (unchged)
Richard Snow 5,300 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Robert Bruce Sold Out
Jeff Auxier 176,374 sh (-0.04%)
Dodge & Cox 58,235,349 sh (-1.75%)
HOTCHKIS & WILEY 3,039,035 sh (-1.89%)
NWQ Managers 5,098,707 sh (-2.39%)
Irving Kahn 1,137,047 sh (-3.36%)
RS Investment Management 1,511,475 sh (-5.9%)
Charles Brandes 3,484,087 sh (-8.58%)
Pioneer Investments 3,536,088 sh (-18.15%)
Jean-Marie Eveillard 320,250 sh (-19.85%)
Diamond Hill Capital 3,525,538 sh (-20.9%)
Joel Greenblatt 21,085 sh (-21.56%)
Jeremy Grantham 8,246,702 sh (-23.36%)
Jim Simons 241,500 sh (-23.61%)
Mark Hillman 9,020 sh (-39.51%)
Ruane Cunniff 5,375 sh (-51.35%)
Chris Davis 5,052,106 sh (-77.45%)
Steven Cohen 14,825 sh (-96.99%)
» More
Q3 2012

MRK Guru Trades in Q3 2012

Robert Bruce 261,500 sh (New)
Ken Fisher 677,943 sh (+3132.15%)
Louis Moore Bacon 97,457 sh (+1887.7%)
Jim Simons 2,071,234 sh (+757.65%)
Joel Greenblatt 42,072 sh (+99.54%)
Pioneer Investments 5,803,317 sh (+64.12%)
Paul Tudor Jones 455,800 sh (+6.42%)
Manning & Napier Advisors, Inc 384,015 sh (+6.37%)
John Buckingham 28,470 sh (+0.09%)
Brian Rogers 6,625,700 sh (unchged)
John Hussman 1,500 sh (unchged)
Prem Watsa 8,000 sh (unchged)
Ruane Cunniff 5,375 sh (unchged)
James Barrow 21,595 sh (unchged)
Murray Stahl 43,771 sh (unchged)
Richard Snow 5,300 sh (unchged)
Mark Hillman Sold Out
Vanguard Health Care Fund 35,390,648 sh (-0.56%)
Jeff Auxier 174,774 sh (-0.91%)
Irving Kahn 1,113,957 sh (-2.03%)
Steven Cohen 14,330 sh (-3.34%)
Bill Frels 131,284 sh (-3.54%)
Diamond Hill Capital 3,345,843 sh (-5.1%)
Dodge & Cox 54,561,349 sh (-6.31%)
NWQ Managers 4,619,439 sh (-9.4%)
RS Investment Management 1,350,575 sh (-10.65%)
HOTCHKIS & WILEY 2,668,549 sh (-12.19%)
Jeremy Grantham 7,185,902 sh (-12.86%)
Tom Russo 6,486 sh (-14.5%)
Charles Brandes 2,421,576 sh (-30.5%)
Mario Gabelli 221,193 sh (-32.69%)
Bill Nygren 1,587,000 sh (-45.02%)
Jean-Marie Eveillard 9,050 sh (-97.17%)
Chris Davis 35,191 sh (-99.3%)
» More
Q4 2012

MRK Guru Trades in Q4 2012

Ray Dalio 44,141 sh (New)
Leon Cooperman 590,000 sh (New)
Steven Cohen 125,674 sh (+777%)
John Hussman 2,625 sh (+75%)
Joel Greenblatt 73,234 sh (+74.07%)
Ken Fisher 1,164,718 sh (+71.8%)
Jean-Marie Eveillard 14,050 sh (+55.25%)
James Barrow 31,995 sh (+48.16%)
John Buckingham 31,748 sh (+11.51%)
RS Investment Management 1,362,975 sh (+0.92%)
Manning & Napier Advisors, Inc 385,926 sh (+0.5%)
Bill Frels 131,724 sh (+0.34%)
Vanguard Health Care Fund 35,490,648 sh (+0.28%)
Prem Watsa 8,000 sh (unchged)
Vanguard Health Care Fund 35,490,648 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Richard Snow 5,300 sh (unchged)
Bill Nygren 1,587,000 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Jeremy Grantham 7,249,102 sh (unchged)
Ruane Cunniff Sold Out
Chris Davis Sold Out
Louis Moore Bacon Sold Out
Jeff Auxier 174,074 sh (-0.4%)
Irving Kahn 1,090,437 sh (-2.11%)
Tom Russo 6,236 sh (-3.85%)
Dodge & Cox 52,449,719 sh (-3.87%)
Diamond Hill Capital 3,181,855 sh (-4.9%)
Murray Stahl 41,335 sh (-5.57%)
Pioneer Investments 5,365,583 sh (-7.54%)
Mario Gabelli 194,926 sh (-11.88%)
NWQ Managers 4,021,109 sh (-12.95%)
Charles Brandes 2,014,574 sh (-16.81%)
HOTCHKIS & WILEY 2,057,435 sh (-22.9%)
Jim Simons 495,834 sh (-76.06%)
Paul Tudor Jones 10,400 sh (-97.72%)
» More
Q1 2013

MRK Guru Trades in Q1 2013

Louis Moore Bacon 100,000 sh (New)
James Barrow 12,483,576 sh (+38917.3%)
Jean-Marie Eveillard 1,537,919 sh (+10846%)
Paul Tudor Jones 285,300 sh (+2643.27%)
Leon Cooperman 1,921,300 sh (+225.64%)
Ray Dalio 95,941 sh (+117.35%)
RS Investment Management 1,692,540 sh (+24.18%)
Mario Gabelli 220,764 sh (+13.26%)
Diamond Hill Capital 3,485,551 sh (+9.54%)
Jeremy Grantham 7,914,302 sh (+9.18%)
Manning & Napier Advisors, Inc 415,439 sh (+7.65%)
Irving Kahn 1,164,661 sh (+6.81%)
Steven Cohen 132,865 sh (+5.72%)
Murray Stahl 43,571 sh (+5.41%)
Bill Frels 135,788 sh (+3.09%)
Richard Snow 5,385 sh (+1.6%)
Vanguard Health Care Fund 35,919,648 sh (+1.21%)
John Buckingham 32,112 sh (+1.15%)
Jeff Auxier 174,624 sh (+0.32%)
Bill Nygren 1,587,000 sh (unchged)
John Hussman 2,625 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Prem Watsa 8,000 sh (unchged)
Tom Russo 6,236 sh (unchged)
Jim Simons Sold Out
Dodge & Cox 51,265,946 sh (-2.26%)
Charles Brandes 1,885,413 sh (-6.41%)
Pioneer Investments 4,761,456 sh (-11.26%)
Ken Fisher 971,824 sh (-16.56%)
HOTCHKIS & WILEY 1,679,235 sh (-18.38%)
Joel Greenblatt 42,504 sh (-41.96%)
NWQ Managers 166,877 sh (-95.85%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
James Barrow 2013-03-31 Add 38917.3%0.99%$40.85 - $45.04 $ 47.5811%12483576
Leon Cooperman 2013-03-31 Add 225.64%0.9%$40.85 - $45.04 $ 47.5811%1921300
Jean-Marie Eveillard 2013-03-31 Add 10846%0.23%$40.85 - $45.04 $ 47.5811%1537919
Joel Greenblatt 2013-03-31 Reduce -41.96%0.07%$40.85 - $45.04 $ 47.5811%42504
Ray Dalio 2013-03-31 Add 117.35%0.02%$40.85 - $45.04 $ 47.5811%95941
Leon Cooperman 2012-12-31 New Buy0.44%$40.64 - $47.96 $ 47.587%590000
Joel Greenblatt 2012-12-31 Add 74.07%0.07%$40.64 - $47.96 $ 47.587%73234
Ray Dalio 2012-12-31 New Buy0.02%$40.64 - $47.96 $ 47.587%44141
Ruane Cunniff 2012-12-31 Sold Out 0.0018%$40.64 - $47.96 $ 47.587%0
Jean-Marie Eveillard 2012-12-31 Add 55.25%$40.64 - $47.96 $ 47.587%14050
James Barrow 2012-12-31 Add 48.16%$40.64 - $47.96 $ 47.587%31995
John Hussman 2012-12-31 Add 75%$40.64 - $47.96 $ 47.587%2625
Charles Brandes 2012-09-30 Reduce -30.5%0.46%$41.2 - $45.24 $ 47.589%2421576
Joel Greenblatt 2012-09-30 Add 99.54%0.06%$41.2 - $45.24 $ 47.589%42072
Jean-Marie Eveillard 2012-09-30 Reduce -97.17%0.05%$41.2 - $45.24 $ 47.589%9050
Mario Gabelli 2012-09-30 Reduce -32.69%0.03%$41.2 - $45.24 $ 47.589%221193
Joel Greenblatt 2012-06-30 Reduce -21.56%0.02%$37.21 - $41.08 $ 47.5824%21085
Ruane Cunniff 2012-06-30 Reduce -51.35%$37.21 - $41.08 $ 47.5824%5375
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Top Ranked Articles about Merck & Co Inc

McDonald's and Four Others Named Dividend Growers Last Week
June 3, 2013
- McDonald's And Four Others Named Dividend Growers Last Week
During the past week GuruFocus recognized five companies as dividend growers. In order to be considered for this list, the company had to: Read more...
Leon Cooperman's First Quarter Increases
May 24, 2013
Leon Cooperman - Leon Cooperman's First Quarter Increases
Leon Cooperman’s current portfolio contains 81 stocks valued at over $6.5 billion. Leon Cooperman increased his holdings in 31 stocks in the most recent quarter; the following five companies represent Cooperman’s five largest increases of the quarter. Newcastle Investment Corporation (NCT) Read more...
52-Week High Companies: LO, MRK, HSY, CL, AEP
July 23, 2012
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs: Lorillard Inc. (LO), Merck & Co. Inc. (MRK), The Hershey Company (HSY), Colgate-Palmolive Company (CL) and American Electric Power (AEP). Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 24.10
MRK's P/E(ttm) is ranked higher than
67% of the 497 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.30 vs. MRK: 24.10 )
MRK' s 10-Year P/E(ttm) Range
Min: 6.33   Max: 139.89
Current: 24.1
6.33
139.89
P/B 2.70
MRK's P/B is ranked higher than
60% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. MRK: 2.70 )
MRK' s 10-Year P/B Range
Min: 1.71   Max: 15
Current: 2.7
1.71
15
P/S 3.20
MRK's P/S is ranked higher than
60% of the 654 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.68 vs. MRK: 3.20 )
MRK' s 10-Year P/S Range
Min: 1.82   Max: 5.48
Current: 3.2
1.82
5.48
PFCF 17.70
MRK's PFCF is ranked higher than
77% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.96 vs. MRK: 17.70 )
MRK' s 10-Year PFCF Range
Min: 7.8   Max: 86.81
Current: 17.7
7.8
86.81
EV-to-EBIT 17.9
MRK's EV-to-EBIT is ranked higher than
70% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.43 vs. MRK: 17.9 )
MRK' s 10-Year EV-to-EBIT Range
Min: 8   Max: 102
Current: 17.9
8
102
PEG 1.2
MRK's PEG is ranked higher than
79% of the 263 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.22 vs. MRK: 1.2 )
MRK' s 10-Year PEG Range
Min: 1.2   Max: 18.82
Current: 1.2
1.2
18.82
Shiller P/E 18.2
MRK's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: vs. MRK: 18.2 )
MRK' s 10-Year Shiller P/E Range
Min: 8.31   Max: 22.98
Current: 18.2
8.31
22.98

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 3.60
MRK's Dividend Yield is ranked higher than
94% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.37 vs. MRK: 3.60 )
MRK' s 10-Year Dividend Yield Range
Min: 1.4   Max: 6.68
Current: 3.6
1.4
6.68
Dividend Payout 0.8667
MRK's Dividend Payout is ranked lower than
60% of the 338 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. MRK: 0.8667 )
MRK' s 10-Year Dividend Payout Range
Min: 0.27   Max: 5.51
Current: 0.87
0.27
5.51
Dividend growth (3y) 2.7
MRK's Dividend growth (3y) is ranked higher than
92% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 2.7 )
MRK' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 6.1
Current: 2.7
0
6.1
Yield on cost (5-Year) 4.05
MRK's Yield on cost (5-Year) is ranked higher than
93% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.29 vs. MRK: 4.05 )
MRK' s 10-Year Yield on cost (5-Year) Range
Min: 1.58   Max: 7.52
Current: 4.05
1.58
7.52
Share Buyback Rate -7.9
MRK's Share Buyback Rate is ranked lower than
61% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: -7.9 )
MRK' s 10-Year Share Buyback Rate Range
Min: 1.4   Max: -9.6
Current: -7.9

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 16
MRK's Price/Net Current Asset Value is ranked higher than
62% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.20 vs. MRK: 16 )
MRK' s 10-Year Price/Net Current Asset Value Range
Min: 9.3   Max: 39.5
Current: 16
9.3
39.5
Price/Tangible Book 12.2
MRK's Price/Tangible Book is ranked lower than
67% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. MRK: 12.2 )
MRK' s 10-Year Price/Tangible Book Range
Min: 3.9   Max: 44.5
Current: 12.2
3.9
44.5
Price/DCF (Projected) 1.2
MRK's Price/DCF (Projected) is ranked higher than
82% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. MRK: 1.2 )
MRK' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 1.6
Current: 1.2
0.8
1.6
Price/Median PS Value 1.1
MRK's Price/Median PS Value is ranked higher than
71% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. MRK: 1.1 )
MRK' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 1.8
Current: 1.1
0.8
1.8
Price/Peter Lynch Fair Value 1.6
MRK's Price/Peter Lynch Fair Value is ranked higher than
72% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. MRK: 1.6 )
MRK' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.5   Max: 3.1
Current: 1.6
1.5
3.1
Price/Graham Number 3.6
MRK's Price/Graham Number is ranked lower than
55% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. MRK: 3.6 )
MRK' s 10-Year Price/Graham Number Range
Min: 1.2   Max: 15
Current: 3.6
1.2
15
Earnings Yield (Greenblatt) 5.60
MRK's Earnings Yield (Greenblatt) is ranked higher than
78% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. MRK: 5.60 )
MRK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 12.6
Current: 5.6
1
12.6
Forward Rate of Return (Yacktman) 20.17
MRK's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. MRK: 20.17 )
MRK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.7   Max: 21.8
Current: 20.17
-8.7
21.8

Business Description

Merck & Co., Inc. was incorporated in New Jersey. It is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health. The Company's operations are principally managed on a products basis and are comprised of four operating segments - Pharmaceutical, Animal Health, Consumer Care and Alliances (which includes revenue and equity income from the Company's relationship with AZLP). The Animal Health, Consumer Care and Alliances segments are not material for separate reporting and are included in all other in the table below. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccines is sold to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets. The Company maintains a number of long-term exploratory and fundamental research programs in biology and chemistry as well as research programs directed toward product development. All of its important products are sold under trademarks. The Company is active in acquiring and marketing products through joint ventures and licenses and has been refining its sales and marketing efforts to further address changing industry conditions. To enhance its product portfolio, it also continues to pursue external alliances. The markets in which the Company conducts its business are highly competitive and often highly regulated. Such competition involves an intensive search for technological innovations and the ability to market these innovations effectively. Additional resources to meet
Company Website
SEC Reports
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS
Traded in other countries:MRK.France, 6MK.Germany
» More Articles for MRK

Headlines

Articles On GuruFocus.com
McDonald's and Four Others Named Dividend Growers Last Week Jun 03 2013 
3 Dogs Of The Dow Jones With Best Buy Recommendations May 27 2013 
Leon Cooperman's First Quarter Increases May 24 2013 
Leon Cooperman’s Bullish Buys: Linn Energy, Chimera Investment, Occidental Petroleum, Qualcomm, Me May 15 2013 
comment on MRK May 09 2013 
3 Dogs of the Dow With Highest Earnings Growth Apr 27 2013 
20 Best-Yielding Health Care Stocks - Less Volatile Than the Market Apr 02 2013 
3 Dogs of the Dow with the Highest Expected Earnings Growth Mar 27 2013 
Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 22 2013 
Why Is Life (LIFE) Cheap? Mar 18 2013 

More From Our Partners
Bond Yields Are Rising -- Do Your Stocks Measure Up? Jun 19 2013 - STREETAUTHORITY

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK